Hong Kong stocks fluctuated | Pharmaceutical stocks generally declined as the Trump administration launched an investigation into pharmaceuticals, but Institutions remain Bullish on the growth potential of Innovative Drugs.

Pharmaceutical stocks generally fell. As of the time of writing, ASCLETIS-B (01672) dropped 12.64%, trading at 5.46 Hong Kong dollars; ALPHAMAB-B (09966) fell 7.74%, trading at 6.44 Hong Kong dollars; HBM HOLDINGS-B (02142) decreased by 7.31%, trading at 7.1 Hong Kong dollars.

Zhitong FinanceApr 16 11:24

Hong Kong Stock Movement | JUNSHI BIO (01877) is currently up over 7%. The chairman intends to increase shareholding by no less than 0.1 billion yuan. The company will announce its first quarter performance at the end of the month.

JUNSHI BIO (01877) is currently up over 7%, with a rise of 7.39% at the time of writing, trading at 15.12 Hong Kong dollars, with a transaction amount of 25.8589 million Hong Kong dollars.

Zhitong FinanceApr 14 10:07

Hong Kong stocks fluctuate | Pharmaceutical stocks lead the gains, ZAI LAB (09688) rises nearly 15%, HBM HOLDINGS-B (02142) rises over 10%.

Pharmaceutical stocks led the gains in the morning session. As of the time of writing, ZAI LAB (09688) rose by 14.86%, reaching HKD 25.5; HBM HOLDINGS-B (02142) increased by 10.07%, reaching HKD 7.87; and REMEGEN (09995) went up by 8.22%, reaching HKD 30.95.

Zhitong FinanceApr 14 09:57

Announcement highlights | Zijin Mining Group's profit in the first quarter increased by over 60% year-on-year; PICC P&C expects a year-on-year net income increase of approximately 80% to 100% in the first quarter.

Zhuoqi Travel collaborates with Gao Yu Technology for a strategic partnership to explore new scenarios in smart transportation with "Flying Autos + Robotaxi"; JUNSHI BIO Chairman Xiong Jun acknowledges the company's long-term investment value and plans to increase Shareholding by no less than 0.1 billion yuan.

cls.cnApr 14 08:07

The chairman of JUNSHI BIO (01877.HK) intends to increase shareholding in AH Stocks within a year, with an amount of at least 0.1 billion yuan.

JUNSHI BIO (01877.HK) announced that Chairman Mr. Xiong Jun intends to increase his Shareholding in the company's A shares and H shares within the next twelve months, with an amount of not less than 0.1 billion RMB, of which the increase in A shares will be not less than 50 million RMB. On April 11, Mr. Xiong signed a supplemental agreement with the concerted action persons and the concerted action persons agreement. Currently, Mr. Xiong and his concerted action persons collectively Hold 18.67% of the company's equity.

AASTOCKSApr 13 20:37

JUNSHI BIO (01877) Chairman Xiong Jun acknowledges the company's long-term investment value and plans to increase shareholding by no less than 0.1 billion yuan.

JUNSHI BIO (01877) announced that Mr. Xiong Jun, the Chairman and Executive Director of the company, plans to increase his shareholding in the company, intending to purchase shares from the...

Zhitong FinanceApr 11 22:22